Preserving brain energy levels to combat Alzheimer's disease
Preservation of brain NAD+ as a novel non-amyloid based therapeutic strategy for Alzheimer’s disease
This study is exploring a new way to help people with Alzheimer's by testing a special compound that aims to keep important energy levels in the brain stable, which could help prevent or improve symptoms of the disease.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Louis Stokes Cleveland VA Medical Center NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project ID | NIH-10863819 on NIH RePORTER |
What this research studies
This research investigates a new approach to treating Alzheimer's disease by focusing on preserving brain levels of nicotinamide adenine dinucleotide (NAD+), a vital energy metabolite that decreases with age and in Alzheimer's patients. The study uses a preclinical mouse model to test a novel compound, P7C3-A20, which is designed to maintain NAD+ levels in the brain. By doing so, the researchers aim to prevent or reverse Alzheimer's-like symptoms and pathology. This approach shifts away from traditional methods that have focused heavily on amyloid-related therapies, which have shown limited success.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 21 and older who are at risk for or diagnosed with Alzheimer's disease.
Not a fit: Patients with early-stage Alzheimer's disease who do not have significant declines in NAD+ levels may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies that effectively prevent or reverse the progression of Alzheimer's disease.
How similar studies have performed: While the approach of targeting NAD+ levels is relatively novel, preliminary studies in other contexts have shown promise in maintaining brain health.
Where this research is happening
Cleveland, United States
- Louis Stokes Cleveland VA Medical Center — Cleveland, United States (Active)
Researchers
- Principal investigator: Pieper, Andrew a — Louis Stokes Cleveland VA Medical Center
- Study coordinator: Pieper, Andrew a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.